



Drug Safety and Risk Management in Clinical Practice

Guest Editor:

Dr. Andreea Maria Farcas

Pharmacovigilance Research
Center, "Iuliu Hatieganu"
University of Medicine and
Pharmacy, 400349 Cluj-Napoca,
Romania

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Dear Colleagues,

Safety monitoring of drugs throughout their whole life cycle is of paramount importance in order to protect public health and fulfill the whole scope of pharmacovigilance. Nevertheless, some adverse effects might not become apparent until after these products have been used for an extended period of time and by a large and diverse population, including those with concurrent illnesses and medications. Therefore, drug safety surveillance through spontaneous reporting systems (SRS) and post-authorization safety studies (PASS) using real-world data will provide information and new insights into the safety profiles of the drugs. This Special Issue welcomes reviews and original papers related to drug safety, such as, but not limited to, studies using active or passive methods for drug/vaccine monitoring (PASS, analysis of data from SRS, including signal detection/disproportionality analysis), studies on risks in special populations, and studies on risk minimization measures, including evaluations of the effectiveness of risk minimization measures.

Dr. Andreea Maria Farcas
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com